{ "docId": "019de515-df71-7068-a98d-cc2a99c8892d", "docSlug": "c88233ba648814c9f5b65afc1926df6d", "documentTitle": "Adagio Therapeutics | Investor Conference Presentation Deck | 11 slides", "authorId": "adagio-therapeutics", "authorName": "Invivyd", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-06-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 2, "pageCount": 11, "prevPage": 1, "nextPage": 3, "slideType": "disclaimer", "function": "front_matter", "density": "balanced", "nDataPoints": 0, "notes": null, "elementsJson": null, "metadataConfidence": 1, "imagePath": null, "slideHref": "/slides/019de515-df71-7068-a98d-cc2a99c8892d/2", "deckHref": "/decks/019de515-df71-7068-a98d-cc2a99c8892d", "deckJsonHref": "/decks/019de515-df71-7068-a98d-cc2a99c8892d.json", "deckAnchorHref": "/decks/019de515-df71-7068-a98d-cc2a99c8892d#slide-2", "components": [ { "bbox": { "h": 0.65, "w": 0.93, "x": 0.034, "y": 0.21 }, "kind": "disclaimer", "text": "This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words such as \"may,\" \"will,\" \"should,\" \"expect,\" \"plan,\" \"anticipate,\" \"seek,\" \"could,\" \"intend,\" \"target,\" \"aim,\" \"project,\" \"designed to,\" \"estimate,\" \"believe,\" \"predict,\" \"potential\" or \"continue\" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning, among other things, our belief that our existing cash resources will be sufficient to fund our operations into the second half of 2024; the future of the COVID-19 landscape including the expectation of continued evolution and emergence of new variants and subvariants; our ongoing research and clinical development plans, including with respect to VYD222; the timing, progress and results of our preclinical studies and clinical trials of our product candidates, including the clinical trial design, objectives and anticipated data readouts from our VYD222 program; our expectation that our platform will rapidly and perpetually deliver a stream of monoclonal antibodies to keep pace with viral evolution and protect vulnerable populations from COVID-19; our expectation to engage in continuous monitoring of viral evolution coupled with rapid antibody discovery and engineering to address the evolving SARS-CoV-2 threat; our expectations regarding the size of target patient populations and the potential market opportunity for our product candidates, as well as our market positioning; our expectations regarding the clinical utility and market acceptance of anti-SARS-CoV-2 monoclonal antibodies (\"mAbs\") and our product candidates; our belief that a mAb therapeutic that offers more robust protection against current SARS-CoV-2 variants would be an important addition to the COVID-19 medicine cabinet, especially for vulnerable populations; our expectations regarding the scope of any approved indication for our product candidates; our ability to successfully commercialize our product candidates; our belief that serum virus neutralizing titers are predictive of protection against symptomatic COVID-19 and have potential to be used as surrogates of clinical efficacy in future trials, potentially accelerating the clinical development path; the potential for an emergency use authorization (\"EUA\") or other regulatory approval of any of our product candidates; our plans to generate a robust pipeline of product candidates which, if authorized or approved, could be used in prevention or treatment of serious viral threats, starting with COVID-19 and expanding into influenza and other high-need indications; and other statements that are not historical fact. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation: our ability to gain alignment with the applicable regulatory authorities on the clinical trial design and development pathway for VYD222 and the timing thereof; the timing and progress of our discovery, preclinical and clinical development activities; our ability to generate and utilize tools to discover and develop a pipeline of antibodies to treat current and potential future SARS-CoV-2 variants; the impacts of the COVID-19 pandemic on our business and those of our collaborators, our clinical trials and our financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; the predictability of clinical success of VYD222 or other product candidates based on neutralizing activity in pre-clinical studies; variability of results in models used to predict activity against SARS-CoV-2 variants of concern; clinical trial site activation or enrollment rates that are lower than expected; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process, including the outcome of our discussions with regulatory authorities concerning our clinical trials and platform-based approach to development; whether we are able to successfully monitor, analyze, engineer and optimize new product candidates and create a stream of monoclonal antibodies to keep pace with viral evolution; whether VYD222 or any other product candidate or combination of candidates is able to demonstrate and sustain neutralizing activity against predominant SARS-CoV-2 variant(s); whether we are able to successfully submit an EUA in the future, and the outcome of any such EUA submission; whether our research and development efforts will identify and result in safe and effective therapeutic options for infectious diseases other than COVID-19; and whether we have adequate funding to meet future operating expenses and capital expenditure requirements. Other factors that may cause our actual results to differ materially from those expressed or implied in the forward-looking statements in this presentation are described under the heading \"Risk Factors\" in our most recent Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission (the \"SEC\"), and in our other filings with the SEC, and in our future reports to be filed with the SEC and available at www.sec.gov. Such risks may be amplified by the impacts of the COVID-19 pandemic. Forward-looking statements contained in this presentation are made as of this date, and we undertake no duty to update such information whether as a result of new information, future events or otherwise, except as required under applicable law.", "attrs": null, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "76690dcf-a611-4d59-8af8-5ef6905c7368", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.046, "w": 0.504, "x": 0.034, "y": 0.876 }, "kind": "source-note", "text": "© 2023 Invivyd, Inc. Invivyd and the Invivyd logo are trademarks of Invivyd, Inc.\nAll trademarks in this presentation are the property of their respective owners.", "attrs": null, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "68d00fdc-2c8b-4ecc-8285-57e8b07c9289", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.04, "w": 0.807, "x": 0.045, "y": 0.132 }, "kind": "title", "text": "CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS", "attrs": null, "subkind": "headline", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "3606f971-e167-4046-afe5-db67c7174728", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }